Tirzepatide: 12,748 published COA source records

398 studies on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.

Bottom line: TitrateLab indexes 12,748 published Tirzepatide COA source records from third-party laboratories, covering 1,778 publicly attributable vendor identities. Across 11,828 records with positive numeric purity, the arithmetic mean is 99.68%. 143 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 25 positive purity results are below 90%; 598 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-17. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.

Tirzepatide average prices

As of 2026-10-19, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.

Strength Average / vial Observed range / vial Average / mg Coverage
5 mg $6.50 $5.50–$7.50 $1.30 2 sources · 2 offers
10 mg $8.88 $8.00–$9.50 $0.89 4 sources · 4 offers
15 mg $9.67 $8.50–$10.50 $0.64 3 sources · 3 offers
20 mg $11.33 $10.50–$12.00 $0.57 3 sources · 3 offers
30 mg $15.00 $12.50–$17.00 $0.50 4 sources · 4 offers
40 mg $19.88 $18.00–$23.00 $0.50 4 sources · 4 offers
50 mg $22.25 $22.00–$22.50 $0.45 2 sources · 2 offers
60 mg $26.12 $25.00–$27.50 $0.44 4 sources · 4 offers
100 mg $35.00 $35.00–$35.00 $0.35 1 source · 1 offer
120 mg $37.00 $37.00–$37.00 $0.31 1 source · 1 offer

Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →

Tirzepatide: published third-party laboratory evidence

All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.

Latest recorded test: 2026-10-17. Aggregate calculated: 2026-10-19T03:01:22.721162+00:00. Calculation time is not a laboratory observation date.

Within that total, 3063 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.

99.68%
Mean positive purity
143
Records reporting zero purity
12748
Published source records
1778
Public vendor identities
25
Positive results below 90%
598
Amount below label >10%

Top 3 vendor evidence profiles for Tirzepatide

Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.

RankVendorDeduplicated certificatesAvg positive purityIdentity adverse results
#1 241 99.6% 0 of 229 (0.0%) 0 0% / not detected · 0 wrong compound · 12 unclassified Reveal with Pro →
#2 195 99.53% 0 of 183 (0.0%) 0 0% / not detected · 0 wrong compound · 12 unclassified Reveal with Pro →
#3 136 99.78% 0 of 96 (0.0%) 0 0% / not detected · 0 wrong compound · 40 unclassified Reveal with Pro →

Vendor identities are included with Pro. Record counts and lab measurements remain visible.

Recent source records: #120652 (99.93%) · #120647 (99.96%) · #120646 (99.94%) · #120632 (99.9%) · #120622 (99.91%) · #120576 (99.8%)

Tirzepatide studies and clinical research

Research tools

Free, no account — handy when you're working with Tirzepatide.

Reconstitution calculator Bac water, concentration & insulin-unit math Verify a COA Look up a report number against our corpus